Literature DB >> 20334913

A novel gallium compound synergistically enhances bortezomib-induced apoptosis in mantle cell lymphoma cells.

Christopher R Chitambar1, David P Purpi.   

Abstract

Combination chemotherapy forms the backbone of cancer treatment. There is a need for new drug combinations for the treatment of mantle cell lymphoma (MCL). Herein, we show that gallium maltolate, a novel gallium compound, synergizes with bortezomib, a proteasome inhibitor, to induce cell death in MCL Granta cells. Cells exposed to either agent displayed caspase-3 activation, a loss of mitochondrial membrane potential, and a decrease in chymotrypsin-like activity. These effects were increased with both agents in combination. Our results show for the first time that the proteasome may be a target for gallium maltolate and suggest that the therapeutic potential of combination bortezomib and gallium maltolate warrants further investigation. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20334913      PMCID： PMC2875307          DOI： 10.1016/j.leukres.2010.02.034

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  14 in total

Review 1.  The machinery of programmed cell death.

Authors:  K C Zimmermann; C Bonzon; D R Green
Journal:  Pharmacol Ther       Date:  2001-10       Impact factor: 12.310

2.  Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors--a CESAR study (Central European Society for Anticancer Drug Research--EWIV).

Authors:  R D Hofheinz; C Dittrich; M A Jakupec; A Drescher; U Jaehde; M Gneist; N Graf von Keyserlingk; B K Keppler; A Hochhaus
Journal:  Int J Clin Pharmacol Ther       Date:  2005-12       Impact factor: 1.366

3.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

4.  Common pathway for tumor cell uptake of gallium-67 and iron-59 via a transferrin receptor.

Authors:  S M Larson; J S Rasey; D R Allen; N J Nelson; Z Grunbaum; G D Harp; D L Williams
Journal:  J Natl Cancer Inst       Date:  1980-01       Impact factor: 13.506

5.  Inhibition of leukemic HL60 cell growth by transferrin-gallium: effects on ribonucleotide reductase and demonstration of drug synergy with hydroxyurea.

Authors:  C R Chitambar; W G Matthaeus; W E Antholine; K Graff; W J O'Brien
Journal:  Blood       Date:  1988-12       Impact factor: 22.113

6.  Synthesis, structure, spectroscopic and in vitro antitumour studies of a novel gallium(III) complex with 2-acetylpyridine (4)N-dimethylthiosemicarbazone.

Authors:  Vladimir B Arion; Michael A Jakupec; Markus Galanski; Peter Unfried; Bernhard K Keppler
Journal:  J Inorg Biochem       Date:  2002-07-25       Impact factor: 4.155

7.  Uptake of gallium-67 by human leukemic cells: demonstration of transferrin receptor-dependent and transferrin-independent mechanisms.

Authors:  C R Chitambar; Z Zivkovic
Journal:  Cancer Res       Date:  1987-08-01       Impact factor: 12.701

8.  Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells.

Authors:  Kenyon G Daniel; Puja Gupta; R Hope Harbach; Wayne C Guida; Q Ping Dou
Journal:  Biochem Pharmacol       Date:  2004-03-15       Impact factor: 5.858

Review 9.  Gallium nitrate in the treatment of lymphoma.

Authors:  David J Straus
Journal:  Semin Oncol       Date:  2003-04       Impact factor: 4.929

10.  Inhibition of the proteasome activity by gallium(III) complexes contributes to their anti prostate tumor effects.

Authors:  Di Chen; Michael Frezza; Rajendra Shakya; Qiuzhi Cindy Cui; Vesna Milacic; Claudio N Verani; Q Ping Dou
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701
View more
  6 in total

1.  Synergistic efficacy of γ-radiation together with gallium trichloride and/or doxorubicin against Ehrlich carcinoma in female mice.

Authors:  Eman Kandil; Nahed Abdel Aziz
Journal:  Tumour Biol       Date:  2015-08-29

Review 2.  Gallium-containing anticancer compounds.

Authors:  Christopher R Chitambar
Journal:  Future Med Chem       Date:  2012-06       Impact factor: 3.808

Review 3.  Iron-targeting antitumor activity of gallium compounds and novel insights into triapine(®)-metal complexes.

Authors:  Christopher R Chitambar; William E Antholine
Journal:  Antioxid Redox Signal       Date:  2012-10-03       Impact factor: 8.401

Review 4.  Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?

Authors:  Mukundan Baskar Mannargudi; Subrata Deb
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-17       Impact factor: 4.322

5.  Development of ga-67 maltolate complex as an imaging agent.

Authors:  Yousef Fazaeli; Amir Reza Jalilian; Mostafa Mohammadpour Amini; Abbas Majdabadi; Ali Rahiminejad; Fatemeh Bolourinovin; Mehraban Pouladi
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

6.  Indium/Gallium Maltolate Effects on Human Breast Carcinoma Cells: In Vitro Investigation on Cytotoxicity and Synergism with Mitoxantrone.

Authors:  Daniele Merli; Antonella Profumo; Nora Bloise; Giulia Risi; Stefano Momentè; Lucia Cucca; Livia Visai
Journal:  ACS Omega       Date:  2018-04-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.